CBLL1 and cancer: While Hakin-1 represents the first reported inhibitor specifically targeting the HYB domain of Hakai, several nutraceuticals, such as celastrol, vinflunine, or silibinin, have also been documented to influence Hakai in several types of cancers [98–100]; however, none of these nutraceuticals are reported to directly and specifically target Hakai.